---
title: "Weekly Recap | Larimar Therapeutics +2.35%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298792511.md"
description: "LRMR.US gained 2.35% for the week to close at $3.92, outperforming the S&P 500 by about 3.15 percentage points while the benchmark fell 0.8%. The four-day stretch was choppy: prices opened at $3.76 on Tuesday and rallied to $4.08 by the close, hit $4.17 intraday on Wednesday before pulling back, slipped again on Thursday, then recovered on heavy Friday turnover. There were no major catalysts, and daily volume tracked close to the 60-day median."
datetime: "2026-09-12T06:12:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298792511.md)
  - [en](https://longbridge.com/en/news/298792511.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298792511.md)
generator: "portal-rs"
---

# Weekly Recap | Larimar Therapeutics +2.35%, most brokers rate it buy

## The Week

LRMR.US gained 2.35% for the week to close at $3.92, outperforming the S&P 500 by about 3.15 percentage points while the benchmark fell 0.8%. The four-day stretch was choppy: prices opened at $3.76 on Tuesday and rallied to $4.08 by the close, hit $4.17 intraday on Wednesday before pulling back, slipped again on Thursday, then recovered on heavy Friday turnover. There were no major catalysts, and daily volume tracked close to the 60-day median.

## Analyst Ratings

Eleven brokers currently cover the stock: nine rate it buy and two rate it overweight, with no hold, underweight or sell ratings, and the consensus recommendation is strong buy. The consensus target price is $14.3, roughly 264.8% above spot, with a wide target range of $5 to $26. The name ranks 123rd out of 506 within the biotech industry.

## The Week Ahead

The macro calendar is crowded: the New York Fed manufacturing index lands on Tuesday (prior 20.6, forecast 14.75), and Wednesday brings retail sales, retail sales ex-autos, retail control, NAHB housing market index, import price index, and EIA weekly crude and Cushing inventory data. Sentiment around small- and mid-cap biotech names could respond to these prints.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)

## Related News & Research

- [Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead](https://longbridge.com/en/news/298782816.md)
- [Why Micron stock just sank](https://longbridge.com/en/news/298685874.md)
- [HC Wainwright Reiterates "Buy" Rating for BridgeBio Pharma (NASDAQ:BBIO)](https://longbridge.com/en/news/298592991.md)
- [Citadel Advisors discloses net short position in Valneva shares](https://longbridge.com/en/news/298606776.md)
- [This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday](https://longbridge.com/en/news/298600420.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**